BridgeBio Pharma (NASDAQ:BBIO) reported quarterly losses of $(0.84) per share which missed the analyst consensus estimate of $(0.67) by 25.37 percent. This is a 4.55 percent increase over losses of $(0.88) per share from the same period last year. The company reported quarterly sales of $194.515 million which beat the analyst consensus estimate of $177.937 million by 9.32 percent. This is a 66.82 percent increase over sales of $116.600 million the same period last year.